US FDA OK's expanded Eribitux use, Qiagen KRAS test
This article was originally published in Scrip
Executive Summary
With the US FDA giving its nod to Qiagen's therascreen KRAS diagnostic kit on 6 July, the agency also gave its blessing to Lilly and Bristol-Myers Squibb to market Erbitux (cetuximab) in combination with the chemotherapy regimen FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) as a first-line treatment for patients with KRAS mutation-negative, epidermal-growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC), based on results using the test.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.